Caio Max Rocha Lima to Clinical Trials as Topic
This is a "connection" page, showing publications Caio Max Rocha Lima has written about Clinical Trials as Topic.
Connection Strength
0.392
-
Rocha Lima CM, Herndon JE, Kosty M, Clamon G, Green MR. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer. 2002 Jan 01; 94(1):181-7.
Score: 0.173
-
Hosein PJ, Rocha-Lima CM. Role of combined-modality therapy in the management of locally advanced rectal cancer. Clin Colorectal Cancer. 2008 Nov; 7(6):369-75.
Score: 0.069
-
Lopes G, Rocha Lima CM. Docetaxel in the management of advanced pancreatic cancer. Semin Oncol. 2005 Apr; 32(2 Suppl 4):S10-23.
Score: 0.054
-
Rocha Lima CM, Urbanic JJ, Lal A, Kneuper-Hall R, Brunson CY, Green MR. Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies. Semin Oncol. 2001 Jun; 28(3 Suppl 10):34-43.
Score: 0.041
-
Rocha Lima CM, Urbanic JJ, Sherman CA, Brescia FJ, Green MR. Docetaxel followed by gemcitabine and irinotecan in solid tumors. Oncology (Williston Park). 2001 Jan; 15(1 Suppl 1):37-45.
Score: 0.040
-
Khanna A, Walker GR, Livingstone AS, Arheart KL, Rocha-Lima C, Koniaris LG. Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg. 2006 May; 10(5):689-97.
Score: 0.015